Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
LIM-domain-only (LMO) proteins are a subset of the LIM-domain protein family and function primarily as transcriptional regulators. They are associated with various cancers, including T cell acute lymphoblastic leukaemia (T-ALL) that resulted from unintended activation ofLMO2by insertional mutagenesis in human gene therapy trials. This Review discusses the roles and potential mechanisms of LMO proteins in cancer and the potential for therapeutic targeting.
The reactivation of wild-type p53 could potentially improve the treatment of many cancer patients. One strategy to achieve this is to target the p53 regulators MDM2 and MDMX. This Review discusses our understanding of how these proteins regulate p53 and the progress that has been made in targeting them.
Two papers providein vivoevidence for plasticity of epithelial and mesenchymal transitions, showing that EMT reversion is required for metastatic outgrowth.
Joan Massagué and colleagues have found that epigenetic changes contribute to metastasis in clear-cell renal-cell carcinomas in which the tumour suppressor gene von Hippel–Lindau (VHL) is inactivated.
As we begin 2013 it's time to take stock of what we do know and what we don't, and consider how best to approach finding new treatments for cancer. Do we embrace complexity or go back to basics?
This Review highlights the complexity and context-dependent roles of both β-catenin-dependent and β-catenin-independent WNT signalling pathways in cancer, as well as some of the ways in which WNT signalling might be targeted therapeutically.
Using theDrosophila melanogastermidgut as a model of intestinal hyperproliferation, Julia Cordero, Owen Sansom and colleagues have identified non-cell-autonomous crosstalk among WNT–MYC, EGFR and JAK–STAT signalling pathways downstream of APC loss; importantly, this pathway may also operate in human colorectal tumours.
